Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.

Saved in:
Bibliographic Details
Title: Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.
Authors: Elsaid MI; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.; Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.; Department of Internal Medicine, Division of Medical Oncology, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Li N; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Firkins SA; Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA., Rustgi VK; Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.; Center for Liver Diseases and Masses, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA., Paskett ED; Division of Population Sciences, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.; Department of Internal Medicine, Division of Cancer Prevention and Control, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Acharya C; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Reddy KR; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA., Chiang CW; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Mumtaz K; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 May; Vol. 59 (9), pp. 1096-1110. Date of Electronic Publication: 2024 Mar 27.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38538967
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Elsaid+MI%22">Elsaid MI</searchLink>; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.; Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.; Department of Internal Medicine, Division of Medical Oncology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Li+N%22">Li N</searchLink>; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Firkins+SA%22">Firkins SA</searchLink>; Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Rustgi+VK%22">Rustgi VK</searchLink>; Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.; Center for Liver Diseases and Masses, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Paskett+ED%22">Paskett ED</searchLink>; Division of Population Sciences, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.; Department of Internal Medicine, Division of Cancer Prevention and Control, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Acharya+C%22">Acharya C</searchLink>; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Reddy+KR%22">Reddy KR</searchLink>; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Chiang+CW%22">Chiang CW</searchLink>; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Mumtaz+K%22">Mumtaz K</searchLink>; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228707234%22">Alimentary pharmacology & therapeutics</searchLink> [Aliment Pharmacol Ther] 2024 May; Vol. 59 (9), pp. 1096-1110. <i>Date of Electronic Publication: </i>2024 Mar 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8707234 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2036 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2202692813%22">02692813 </searchLink><i>NLM ISO Abbreviation: </i>Aliment Pharmacol Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38538967
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/apt.17925
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1096
    Titles:
      – TitleFull: Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Elsaid MI
      – PersonEntity:
          Name:
            NameFull: Li N
      – PersonEntity:
          Name:
            NameFull: Firkins SA
      – PersonEntity:
          Name:
            NameFull: Rustgi VK
      – PersonEntity:
          Name:
            NameFull: Paskett ED
      – PersonEntity:
          Name:
            NameFull: Acharya C
      – PersonEntity:
          Name:
            NameFull: Reddy KR
      – PersonEntity:
          Name:
            NameFull: Chiang CW
      – PersonEntity:
          Name:
            NameFull: Mumtaz K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2024 May
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2036
          Numbering:
            – Type: volume
              Value: 59
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Alimentary pharmacology & therapeutics
              Type: main
ResultId 1